April 21, 2021 | Berlin
Eckert & Ziegler Eurotope GmbH successfully passes system audit for ISO 9001:2015 certification
Eckert & Ziegler Eurotope’s quality management underwent an extensive system audit by TÜV SÜD in late March. The successful completion of this audit certifies that the system in place complies with the current requirements of the ISO 9001:2015 norm.
ISO 9001 defines the criteria for a company’s quality management system, focusing on continuous improvement of internal processes to guarantee consistent and traceable products and services for the customer. Due to the successful audit, Eckert & Ziegler Eurotope GmbH has been accredited with its compliance for the 10th consecutive time.
“As a manufacturer of laboratory equipment and quality control devices used in GMP environments, we have an obligation to our customers, to have a strong quality management system in place. This is especially crucial when it comes to products and services concerning the production of radiopharmaceuticals. The ISO 9001:2015 certification by an impartial authority shows that we are always striving to improve our processes to offer highest quality products and services to our customers” stated Dr. Sven-Peter Heyn, Managing Director of Eckert & Ziegler Eurotope GmbH.
The corresponding certificate can be accessed here.
About Eckert & Ziegler Eurotope GmbH
Eurotope GmbH belongs to the Eckert & Ziegler group and represents the Lab Devices business unit of the Medical Segment. The company develops, manufactures and sells device systems and accessories for radionuclide labeling and quality control of radiopharmaceuticals. The products are used in research and routine manufacturing of patient doses for cancer diagnosis and therapy in hospitals as well as in industrial manufacturing processes for radioactively labeled compounds and drugs.
As part of the Medical Segment, Eurotope GmbH contributes to provide complete solutions to Eckert & Ziegler´s worldwide customers in the nuclear medicine and pharma industry. The comprehensive product and service portfolio ranges from customized hot cell solutions and in-cell equipment over radionuclides to contract development and GMP-manufacturing services for radiopharmaceuticals through all stages from early clinical to commercial supply.